Irbesartan + Hidroclorotiazida Pharmakern (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑induced vasoconstriction and aldosterone secretion. This leads to reduced systemic vascular resistance and lower blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure response, renal function, and overall clinical condition. Dosage adjustments are made according to therapeutic goals and tolerability.

Safety in pregnancy and lactation has not been established. The combination is generally avoided during pregnancy unless the potential benefit justifies the risk. Women who are breastfeeding should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy agents such as irbesartan alone, the addition of hydrochlorothiazide provides a diuretic effect that often yields greater blood‑pressure reduction, especially in patients who need volume control. It is similar in efficacy to other ARB‑thiazide combinations like losartan/HCTZ.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the package is tightly closed to maintain product stability.

The medication is taken orally as a tablet, usually once daily. It should be swallowed whole with a glass of water and can be taken with or without food, unless otherwise directed by a healthcare professional.

Serious risks include severe dehydration, marked electrolyte disturbances (especially low potassium), acute kidney injury, angioedema, and life‑threatening hypotension. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight loss, or fainting.

The combination should be avoided in patients with known hypersensitivity to irbesartan or hydrochlorothiazide, severe renal impairment, hyperkalemia, or those who are pregnant unless the benefits outweigh the risks. Clinicians should also assess for contraindications before initiating therapy.